CD163 and metastatic malignant neoplasm in the lymph nodes: A study by Koelzer et al. [34], found an association between a high CD163+ TAM number and factors associated with favorable disease outcome, such as a lower incidence of lymph node metastasis and less advanced T-stage; however, a statistically significant survival benefit was not demonstrated for these patients, although a difference in survival time was observed [34].